Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.42+0.01 (+3.28%)
Close on Nov 19, 2026Market cap $117.02MP/E –Yield –
Akebia Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Akebia Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $40.26M. For fiscal 2025 it was $67.70M. The highest annual figure on record is $67.70M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.70M | – |
| FY2024 | Dec 31, 2024 | -$40.69M | – |
| FY2023 | Dec 31, 2023 | -$23.38M | – |
| FY2022 | Dec 31, 2022 | -$73.27M | – |
| FY2021 | Dec 31, 2021 | -$253.02M | – |
| FY2020 | Dec 31, 2020 | -$110.71M | – |
| FY2019 | Dec 31, 2019 | -$264.10M | – |
| FY2018 | Dec 31, 2018 | -$99.10M | – |
| FY2017 | Dec 31, 2017 | -$57.78M | -204.6% |
| FY2016 | Dec 31, 2016 | $55.24M | – |
| FY2015 | Dec 31, 2015 | -$52.82M | – |
| FY2014 | Dec 31, 2014 | -$27.71M | – |
| FY2013 | Dec 31, 2013 | -$11.35M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.45M | -89.0% |
| Q1 FY2026 | Mar 31, 2026 | -$21.27M | – |
| Q4 FY2025 | Dec 31, 2025 | $31.06M | – |
| Q3 FY2025 | Sep 30, 2025 | $28.03M | – |
| Q2 FY2025 | Jun 30, 2025 | $22.22M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.10M | -378.2% |
| Q1 FY2024 | Mar 31, 2024 | -$19.43M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.17M | -121.2% |
| Q2 FY2023 | Jun 30, 2023 | $3.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.54M | – |
| Q4 FY2022 | Dec 31, 2022 | -$54.68M | – |
| Q3 FY2022 | Sep 30, 2022 | $33.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.66M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$62.81M | – |
| Q3 FY2021 | Sep 30, 2021 | -$56.27M | – |
| Q2 FY2021 | Jun 30, 2021 | -$63.14M | -269.8% |
| Q1 FY2021 | Mar 31, 2021 | -$70.81M | – |
| Q4 FY2020 | Dec 31, 2020 | -$31.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$27.19M | -421.4% |
| Q2 FY2020 | Jun 30, 2020 | $37.18M | – |
| Q1 FY2020 | Mar 31, 2020 | -$89.59M | – |
| Q4 FY2019 | Dec 31, 2019 | -$92.36M | – |
| Q3 FY2019 | Sep 30, 2019 | $8.46M | – |
| Q2 FY2019 | Jun 30, 2019 | -$40.34M | -557.3% |
| Q1 FY2019 | Mar 31, 2019 | -$139.86M | – |
| Q4 FY2018 | Dec 31, 2018 | -$74.53M | – |
| Q3 FY2018 | Sep 30, 2018 | -$12.77M | – |
| Q2 FY2018 | Jun 30, 2018 | $8.82M | -63.6% |
| Q1 FY2018 | Mar 31, 2018 | -$20.63M | – |
| Q4 FY2017 | Dec 31, 2017 | -$16.83M | -117.6% |
| Q3 FY2017 | Sep 30, 2017 | -$55.21M | – |
| Q2 FY2017 | Jun 30, 2017 | $24.22M | – |
| Q1 FY2017 | Mar 31, 2017 | -$9.96M | – |
| Q4 FY2016 | Dec 31, 2016 | $95.62M | – |
| Q3 FY2016 | Sep 30, 2016 | -$29.50M | – |
See a number that looks wrong?